Initial clinical studies with 5-iodo-2'-deoxyuridine.

Paper

Initial clinical studies with 5-iodo-2'-deoxyuridine.

Published May 1, 1961 · P. Calabresi, S. Cardoso, S. C. Finch

Cancer research

108

Citations

3

Influential Citations

Abstract

Summary The results of preliminary clinical pharmacological investigations of 5-iodo-2′-deoxyuridine (IUDR), an analog of thymidine, are reported. With dosages of 100–120 mg IUDR/kg, infused intravenously during periods of 2–3 hours daily for 5 or 6 days, studies of the urinary excretion of IUDR, 5-iodouracil, and iodide indicated that significant blood levels of IUDR were maintained for approximately 4 hours. The major toxic effects of such dosage regimens were stomatitis, leukopenia, and alopecia. In the present series, evidence of modest tumor inhibition was observed in six of sixteen patients with advanced neoplastic disease. Possible areas for future investigations with this compound, particularly in combination with other antimetabolites and radiation therapy, have been discussed.

Highly Cited

Study Snapshot

5-iodo-2′-deoxyuridine shows modest tumor inhibition in advanced neoplastic disease patients, with potential for future investigations in combination with other antimetabolites and radiation therapy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Initial clinical studies with 5-iodo-2'-deoxyuridine.

References

Citations